title: A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction.
abstract: OBJECTIVE
  We prospectively compared coronary endothelial dysfunction in patients with zotarolimus-eluting stent (ZES) versus sirolimus-eluting stent (SES) implantation at 6-month follow-up.
  
  
  BACKGROUND
  A ZES has been associated with uniform and rapid healing of the endothelium.
  
  
  METHODS
  Fifty patients were randomly treated with intravascular ultrasound-guided stenting with a single stent to the mid-segment of the left anterior descending artery (20 ZES, 20 SES, and 10 bare-metal stents), and endothelial function was estimated before and after intervention at 6-month follow-up by incremental acetylcholine (Ach) (10, 20, 50, and 100 microg/min) and nitrate (200 microg/min) infusions into the left coronary ostium. The vascular response was quantitatively measured in the 5-mm segments proximal and distal to the stent.
  
  
  RESULTS
  In the drug-eluting stent groups, more intense vasoconstriction to incremental doses of Ach was observed at 6-month follow-up compared with the responses before stenting. Endothelial function associated with the ZES was more preserved at 6-month follow-up compared with the SES. Vasoconstriction to Ach was more prominent in the distal segments than the proximal segments in both the ZES and SES groups. Endothelium-independent vasodilation to nitrate did not differ significantly among the study groups.
  
  
  CONCLUSIONS
  Vasoconstriction in response to Ach in the peri-stent region was less pronounced in the ZES group than the SES group at 6-month follow-up, which suggests that endothelial function associated with ZES can be more preserved than the SES.
authors.affiliation: Cardiovascular Center, Korea University, Guro Hospital, Seoul, Korea.
authors.forename: Jin Won
authors.initials: JW
authors.lastname: Kim
authors.forename: Hong Seog
authors.initials: HS
authors.lastname: Seo
authors.forename: Jae Hyoung
authors.initials: JH
authors.lastname: Park
authors.forename: Jin Oh
authors.initials: JO
authors.lastname: Na
authors.forename: Cheol Ung
authors.initials: CU
authors.lastname: Choi
authors.forename: Hong Euy
authors.initials: HE
authors.lastname: Lim
authors.forename: Eung Ju
authors.initials: EJ
authors.lastname: Kim
authors.forename: Seung-Woon
authors.initials: SW
authors.lastname: Rha
authors.forename: Chang Gyu
authors.initials: CG
authors.lastname: Park
authors.forename: Dong Joo
authors.initials: DJ
authors.lastname: Oh
mesh_terms: D023903:Coronary Restenosis / Q000188:drug therapy* / Q000517:prevention & control; D003331:Coronary Vessels / Q000187:drug effects / Q000503:physiopathology*; D054855:Drug-Eluting Stents; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012372:ROC Curve; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013997:Time Factors; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D007166:Immunosuppressive Agents; C489443:zotarolimus; D020123:Sirolimus